Clin Orthop Surg.  2012 Sep;4(3):181-187. 10.4055/cios.2012.4.3.181.

Minocycline-induced Periarticular Black Bones in Inflamed Joints Which Underwent Arthroplastic Reconstruction

Affiliations
  • 1Department of Orthopedic Surgery, Yamagata University School of Medicine, Yamagata, Japan. yangsuran@gmail.com
  • 2Department of Medicine, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland.
  • 3Department of Orthopedic Surgery, Sanyudo Hospital, Yonezawa, Japan.
  • 4Department of Orthopedic Surgery, Yamagata Saisei Hospital, Yamagata, Japan.

Abstract

BACKGROUND
Minocycline-induced pigmentation of bone (black bone) is well described in tooth-bearing intra-oral bone, but is less known in periarticular bone in patients who have undergone total joint arthroplasty. On a retrospective basis, we investigated the short-term clinico-radiological results of total joint arthroplasties in which the patient developed minocycline-induced periarticular black bone.
METHODS
We found 5 cases (0.08%), in 4 patients, of periarticular bone pigmentation revealed during total joint arthroplasties (2 hips, 2 knees, and 1 ankle) in our series of total joint surgeries (6,548 cases) over a 10-year time period in our 3 institutes. Their mean age was 56 years at surgery. All patients had received long-term minocycline treatment. Mean dosage and duration of minocycline was 160 mg/day and 2.2 years, respectively. Minocycline had been prescribed for reactive arthritis (one), rheumatoid arthritis (two) and late infection after total joint arthroplasty (two patients). Mean follow-up period was 3.4 years after the surgeries.
RESULTS
All cases had black or brown pigmentation in the periarticular bones during the surgery. There was no pigmentation in the cartilage or soft tissues of the joints. The mean Japanese Orthopaedic Association (JOA) score or Japanese Society for Surgery of the Foot (JSSF) scale for rheumatoid arthritis foot and ankle joints at latest follow-up (case 1, 66; case 2, 87; case 3, 77; case 4, 77; case 5, 80) improved compared to those of pre-surgery (case 1, 47; case 2, 45; case 3, 55; case 4, 34; case 5, 55). No implant loosening was noted on radiographic examination during the follow-up period. No abnormal bone formation, bone necrosis, hemosiderin deposition, malignancy or metallic debris was found on histological examination.
CONCLUSIONS
No clinico-radiological symptoms of total joint arthroplasties showed in the patients with minocycline-induced periariticular black bone in the short-term. Systemic minocycline treatment has the potential to induce significant black pigmentation of many tissues. In particular, minocycline-induced pigmentation of periarticular bone may be accelerated by inflammation due to rheumatic or pyogenic arthritis. Surgeons should recognize the risk of bone pigmentation in inflamed joints due to the systemic treatment of minocycline and explore its influence on periarticular bone and total joint arthroplasty in the long-term.

Keyword

Joint; Periarticular bone; Black bone; Minocycline; Total joint arthroplasty

MeSH Terms

Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents/*adverse effects/therapeutic use
Antibiotic Prophylaxis/adverse effects
Arthritis/drug therapy/*pathology/prevention & control
Arthroplasty, Replacement/*methods
Bone and Bones/*drug effects/pathology
Female
Humans
Male
Middle Aged
Minocycline/*adverse effects/therapeutic use
Retrospective Studies
Skin/pathology
Skin Pigmentation

Figure

  • Fig. 1 Case 1: A 75-year-old woman had received 200 mg/day minocycline for 2 years to treat reactive arthritis. (A) Anteroposterior radiographic views of the right ankle preoperatively and (B) at the last follow-up. Preoperatively, her right ankle shows end-stage osteoarthritic changes. (C) Black pigmentation and discoloration of the distal part of the tibia and talus (indicated by arrows) were observed during total ankle arthroplasty; this was due to long-term minocycline medication. (D) Hematoxylin-eosin-stained microphotograph of the black bone removed from the distal end of the tibia shows normal bone structure; there were no bone necrosis, deposition of hemosiderin, malignancy, or abnormalities of bone matrix (×200).

  • Fig. 2 Case 4: A 33-year-old man had received 200 mg/day minocycline for 7 months for infection of his total hip arthroplasty. Photographic views of minocycline-induced skin hyperpigmentation on the lower legs (A) at pre-revision surgery and (B) 37 months after discontinuing minocycline. Note the resolution of skin pigmentation after discontinuation of minocycline.


Reference

1. Kelly RG, Kanegis LA. Metabolism and tissue distribution of radioisotopically labelled minocycline. Toxicol Appl Pharmacol. 1967. 11(1):171–183.
2. Eisen D, Hakim MD. Minocycline-induced pigmentation. Incidence, prevention and management. Drug Saf. 1998. 18(6):431–440.
3. Pandit S, Hadden W. Black pigmentation of bone due to long-term minocycline use. Surgeon. 2004. 2(4):236–237.
4. Hepburn MJ, Dooley DP, Hayda RA. Minocycline-induced black bone disease. Orthopedics. 2005. 28(5):501–502.
Article
5. Treister NS, Magalnick D, Woo SB. Oral mucosal pigmentation secondary to minocycline therapy: report of two cases and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004. 97(6):718–725.
Article
6. Sanchez AR, Rogers RS 3rd, Sheridan PJ. Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity. Int J Dermatol. 2004. 43(10):709–715.
Article
7. LaPorta VN, Nikitakis NG, Sindler AJ, Reynolds MA. Minocycline-associated intra-oral soft-tissue pigmentation: clinicopathologic correlations and review. J Clin Periodontol. 2005. 32(2):119–122.
Article
8. Angeloni VL, Salasche SJ, Ortiz R. Nail, skin, and scleral pigmentation induced by minocycline. Cutis. 1987. 40(3):229–233.
Article
9. Benitz KF, Roberts GK, Yusa A. Morphologic effects of minocycline in laboratory animals. Toxicol Appl Pharmacol. 1967. 11(1):150–170.
Article
10. Attwood HD, Dennett X. A black thyroid and minocycline treatment. Br Med J. 1976. 2(6044):1109–1110.
11. Sabroe RA, Archer CB, Harlow D, Bradfield JW, Peachey RD. Minocycline-induced discolouration of the sclerae. Br J Dermatol. 1996. 135(2):314–316.
12. Wolfe ID, Reichmister J. Minocycline hyperpigmentation: skin, tooth, nail, and bone involvement. Cutis. 1984. 33(5):457–458.
Article
13. Rumbak MJ, Pitcock JA, Palmieri GM, Robertson JT. Black bones following long-term minocycline treatment. Arch Pathol Lab Med. 1991. 115(9):939–941.
Article
14. McCleskey PE, Littleton KH. Minocycline-induced blue-green discoloration of bone: a case report. J Bone Joint Surg Am. 2004. 86(1):146–148.
Article
15. Ueno R. Staging of osteoarthritis of the hip joint according to the roentgenographic findings. J Jpn Orthop Assoc. 1971. 45(10):826–828.
Article
16. Koshino T. Japanese Orthopaedic Association knee scoring system. J Jpn Orthop Assoc. 1988. 62(8):900–902.
Article
17. Niki H, Aoki H, Inokuchi S, et al. Development and reliability of a standard rating system for outcome measurement of foot and ankle disorders II: interclinician and intraclinician reliability and validity of the newly established standard rating scales and Japanese Orthopaedic Association rating scale. J Orthop Sci. 2005. 10(5):466–474.
Article
18. Takagi M, Ida H, Kobayashi S, Ishii M, Osanai T, Konttinen YT. Ochronotic spondylarthropathy: two case reports of progressive destructive changes in the hip. Mod Rhumatol. 2003. 13(1):81–86.
19. Kelley SS, Lachiewicz PF, Gilbert MS, Bolander ME, Jankiewicz JJ. Hip arthroplasty in hemophilic arthropathy. J Bone Joint Surg Am. 1995. 77(6):828–834.
20. Goldman AB, DiCarlo EF. Pigmented villonodular synovitis: diagnosis and differential diagnosis. Radiol Clin North Am. 1988. 26(6):1327–1347.
Article
21. Iida H, Kaneda E, Takada H, Uchida K, Kawanabe K, Nakamura T. Metallosis due to impingement between the socket and the femoral neck in a metal-on-metal bearing total hip prosthesis: a case report. J Bone Joint Surg Am. 1999. 81(3):400–403.
Article
22. Khan RJ, Wimhurst J, Foroughi S, Toms A. The natural history of metallosis from catastrophic failure of a polyethylene liner in a total hip. J Arthroplasty. 2009. 24(7):1144.e1–1144.e4.
Article
23. Huber M, Reinisch G, Zenz P, Zweymuller K, Lintner F. Postmortem study of femoral osteolysis associated with metal-on-metal articulation in total hip replacement: an analysis of nine cases. J Bone Joint Surg Am. 2010. 92(8):1720–1731.
Article
24. Ragucci BD. Green bones and tooth roots: minocycline? Schoch Lett. 1979. 29(1):3.
Article
25. Fendrich P, Brooke RI. An unusual case of oral pigmentation. Oral Surg Oral Med Oral Pathol. 1984. 58(3):288–289.
Article
26. Westbury LW, Najera A. Minocycline-induced intraoral pharmacogenic pigmentation: case reports and review of the literature. J Periodontol. 1997. 68(1):84–91.
27. Cockings JM, Savage NW. Minocycline and oral pigmentation. Aust Dent J. 1998. 43(1):14–16.
28. Roberts G, Capell HA. The frequency and distribution of minocycline induced hyperpigmentation in a rheumatoid arthritis population. J Rheumatol. 2006. 33(7):1254–1257.
Article
29. Bowles WH. Protection against minocycline pigment formation by ascorbic acid (vitamin C). J Esthet Dent. 1998. 10(4):182–186.
Article
Full Text Links
  • CIOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr